Registry for new treatments in patients with atopic dermatitis
BioDay Registry: Prospective, Observational Data Collection Regarding the Use of New Systemic Treatment Options in Patients with Atopic Diseases in Daily Practice
UMC Utrecht · NCT03549416
This study is collecting information from people with atopic dermatitis to see how well new treatments work and how they affect other related conditions like food allergies and asthma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1200 (estimated) |
| Ages | 0 Years and up |
| Sex | All |
| Sponsor | UMC Utrecht (other) |
| Locations | 14 sites (Nijmegen, Gelderland and 13 other locations) |
| Trial ID | NCT03549416 on ClinicalTrials.gov |
What this trial studies
The BioDay Registry collects data on the effectiveness and safety of new systemic treatments for atopic dermatitis, including biologics and Janus kinase inhibitors. This observational study involves multiple centers and aims to gather real-world evidence on treatment outcomes and the impact on related atopic conditions such as food allergies and asthma. Patients of all ages receiving these treatments will be invited to participate by completing questionnaires about their experiences.
Who should consider this trial
Good fit: Ideal candidates include both adult and pediatric patients currently receiving new systemic treatments for atopic dermatitis.
Not a fit: Patients who are unable or unwilling to complete questionnaires will not benefit from this study.
Why it matters
Potential benefit: If successful, this registry could provide valuable insights that improve treatment strategies for patients with atopic dermatitis.
How similar studies have performed: Other studies have successfully utilized registries to gather real-world data on treatment effectiveness, making this approach promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All adult and paediatric patients treated with new systemic treatments for AD will be asked for participation in the BioDay Registry Exclusion Criteria: * Patients are not eligible for enrolment in case of presumed inability to answer questionnaires or not willing to answer questionnaires and will be excluded.
Where this trial is running
Nijmegen, Gelderland and 13 other locations
- Radboud University Medical Center — Nijmegen, Gelderland, Netherlands (RECRUITING)
- Isala Dermatologisch Centrum — Zwolle, Overijssel, Netherlands (RECRUITING)
- Medisch Centrum Leeuwarden — Leeuwarden, Provincie Friesland, Netherlands (RECRUITING)
- University Medical Center Groningen — Groningen, Provincie Groningen, Netherlands (RECRUITING)
- IJsselland Ziekenhuis — Capelle aan den IJssel, South Holland, Netherlands (RECRUITING)
- University Medical Center Utrecht — Utrecht, Utrecht, Netherlands (RECRUITING)
- Meander Medisch Centrum — Amersfoort, Netherlands (RECRUITING)
- Reinier de Graaf ziekenhuis — Delft, Netherlands (RECRUITING)
- Catharina ziekenhuis — Eindhoven, Netherlands (RECRUITING)
- Spaarne Gasthuis — Haarlem, Netherlands (RECRUITING)
- Maastricht Univeristy Medical Center — Maastricht, Netherlands (RECRUITING)
- Haga ziekenhuis — The Hague, Netherlands (RECRUITING)
- Diakonessenhuis — Utrecht, Netherlands (RECRUITING)
- St Antonius ziekenhuis — Utrecht, Netherlands (RECRUITING)
Study contacts
- Principal investigator: Marjolein de Bruin-Weller, Md, PhD — UMC Utrecht
- Study coordinator: Marlies de Graaf, MD, PhD
- Email: M.deGraaf-10@umcutrecht.nl
- Phone: +31887571134
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Atopic Dermatitis, Atopic dermatitis, Dupilumab, Dupixent, BioDay, Daily practice, Real world, Atopic Diseases Registry